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Background: Cystic fibrosis (CF) clinically manifests with various levels of severity, which are thought to be modulated
by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR), modifier genes, and the
environment. This study verified whether polymorphisms in modifier genes associated with glutathione (GSH)
metabolism influence CF severity.
Methods: A cross-sectional study of 180 CF patients was carried out from 2011 to 2012. We analyzed CFTR
mutations, polymorphisms (GSTM1 and GSTT1 deletions, GSTP1 + 313A > G, GCLC-129C > T, and GCLC-3506A > G)
in modifier genes and CF clinical severity as assessed by 28 clinical and laboratory variables.
Results: Significant associations were found between modifier gene polymorphisms and particular phenotypes or
genotype changes. These included GCLC-129C > T with a higher frequency of the Pseudomonas aeruginosa mucoid to
CC genotype (p = 0.044), and GCLC-3506A > G with a higher frequency of the no-mucoid P. aeruginosa (NMPA) to
AA genotype (p = 0.012). The GSTT1 deletion was associated with a higher frequency of the NMPA to homozygous
deletion (p = 0.008), GSTP1 + 313A > G with a minor risk of osteoporosis (p = 0.036), and patient age ≤ 154 months
(p = 0.044) with the AA genotype. The Bhalla score was associated with GCLC-3506A > G (p = 0.044) and GSTM1/GSTT1
deletion polymorphisms (p = 0.02), while transcutaneous hemoglobin oxygen saturation levels were associated with
GSTT1 deletions (p = 0.048).
Conclusion: CF severity is associated with polymorphisms in GSH pathways and CFTR mutations.
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Cystic fibrosis (CF) presents with broad phenotypic vari-
ability, even in patients with identical mutations in the
causative gene, cystic fibrosis transmembrane conductance
regulator (CFTR) [1]. Explanations for this include envir-
onmental factors [2], medical management [3], nutritional
status [4], emotional maladjustments [5], socioeconomic
status [3], CFTR mutations [1], and modifier genes [1,3,6].
In this context, CF modifier genes have been studied with* Correspondence: fernandolimamarson@hotmail.com
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reproduction in any medium, provided the orthe aim of increasing chlorine transport and/or controlling
pulmonary inflammation and infection [6-9].
Our group studied CF severity in association with
several modifier genes including polymorphisms in the
genes: MBL-2, TGF-β1, CD14 [10], ACE [11], ADRB2 [12],
TCF7L2 [13], ADRA2A [14], COX-2 [15] and IFRD1 [16].
These polymorphisms were associated with clinical variables
including lung and digestive disease.
Glutathione (GSH) is a tripeptide composed of L-
cysteine, L-glutamic acid, and glycine. It is a crucial part
of the intracellular defense system, which protects the
epithelium against the injuries and inflammation [17]
common to CF that are caused by oxidation [18]. As
polymorphisms can alter the GSH metabolic pathway,
genetic variations of this pathway have previously been
studied in association with CF [19-21].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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comprises proteins with distinct genetic origins that form
a detoxification system, which protects the human body
against electrophilic compounds and oxidative stress [22].
The GST protein is responsible for combining compounds
that cause oxidative stress with GSH. It is therefore pos-
sible that GST polymorphisms are involved in CF severity
[18,22], especially with regard to pulmonary disease.
Genetic variants of the GST genes include glutathione
S-transferase mu 1 (GSTM1) located on chromosome
1p13.3, and glutathione S-transferase theta 1 (GSTT1)
on chromosome 22q11.23 [23], which both exhibit poly-
morphic deletions [22,24]. The null GST allele does not
encode a GST protein, so homozygous genotypes are
associated with increased CF clinical severity [25,26]. The
glutathione S-transferase pi gene (GSTP1) on chromosome
11q13 [23] is associated with xenobiotic metabolism and
susceptibility to cancer and other diseases [22]. Its most
commonly studied polymorphism is an A→ G base ex-
change at the +313 position (substituting isoleucine by
valine at codon 105) [27].
The glutamate-cysteine ligase, catalytic subunit gene
(GCLC) on chromosome 6p12 [23] encodes the catalytic
subunit of glutamate-cysteine ligase (GCL), which is the
first limiting enzyme in GSH synthesis [28]. The GCL
holoenzyme is a heterodimer of approximately 104 kDa
composed of catalytic-GCLC and regulatory-GCLR sub-
units [18]. The -129C > T and -3506A > G polymorphisms
of GCLC are located in the promoter region and are re-
sponsible for reduced production of GSH [18,28].
Of these genes, GSTP1 is associated with hepatic disease
[19] and infection [20], GSTM1 with greater CF clinical
severity [21], GSTT1 with no CF clinical variables, while
GCLC has not been previously studied in relation to CF.
However, as the action of the GSH protein is closely
related to that of CFTR [29], it is conceivable that
GCLC and GST polymorphisms influence CF severity
[19-21,26,30]. This study therefore aimed to determine
whether genetic polymorphisms in the GSH metabolic
pathway are associated with CF severity under different
phenotypes of the disease.
Methods
This cross-sectional study was conducted in a university
center for CF care between 2011 and 2012. Two hundred
and fifteen patients were selected for the study, of which
35 were excluded for not signing the consent form or
because of a lack of clinical data for statistical analysis. CF
diagnosis was confirmed if levels of chloride in the sweat
exceeded 60 mEq/L and by CFTRmutation screening when
possible. CF patients, with no identified CFTR mutation or
with one CFTR mutation screened, were classified as CF
disease, considering: (i) all patients had levels of chloride in
the sweat exceeded 60 mEq/L; (ii) CF clinical symptomswere diagnosed in all patients as: chronic obstructive
pulmonary disease, bacteria in sputum, spirometry with
obstruction values for forced expiratory volume in the first
second (FEV1%), associated comorbidities (i.e. osteoporosis,
nasal polyps, diabetes mellitus and pancreatic insufficiency);
(iii) the dosage of active CFTR in epithelium via rectal bi-
opsy was performed - all patients included had abnormal
values for biopsy – absence of active CFTR was found; (iv)
nasal potential was realized in some patients - all values
were changed – but the comparison was not performed,
taking into account a control standard curve, being an in-
conclusive data. By this method was possible to exclude
Cystic Fibrosis Related Diseases.
No patients were diagnosed by a neonatal screening
test. Patient DNA was obtained by phenol-chloroform
extraction and 50 ng/mL was used for analysis as evaluated
by a GE NanoVue™ Spectrophotometer (GE Healthcare
Biosciences, Pittsburgh, PA, USA).
Clinical variables
Several clinical variables were employed, including
Shwachman-Kulczycki, Kanga and Bhalla clinical scores
[31]; body mass index (BMI) [for patients older than
19 years, the BMI = weight/(height)2 formula was used,
while remaining patients used the WHO ANTHRO pro-
gram (children 0–5 years of age) or the WHO ANTHRO
PLUS program (children 5–19 years of age)]; patient’s
age (≤154 and >154 months); time to diagnosis (≤24
and >24 months); time of first clinical symptoms (digest-
ive: ≤3 and >3 months; pulmonary: ≤6 and >6 months);
time to first colonization by Pseudomonas aeruginosa
(≤31 and >31 months); bacteria in the respiratory airways:
mucoid P. aeruginosa and no mucoid P. aeruginosa,
Achromobacter xylosoxidans, Burkholderia cepacia and
Staphylococcus aureus - the positive status was evaluated
considering chronic infection (patients in whom more than
50% of the preceding 12 months was culture positive) +
intermittent infection (patients with less than 50% of
cultures positive). A patient was negative considering
as free of bacterium (when no bacterium was grown
from samples in the previous 12 months, despite a history
of prior colonization) + never infected (patients in whom
the bacterium) has never been cultured, i.e. this consensus
was formulated for P. aeruginosa, but in our data was used
for all bacteria [32]; transcutaneous hemoglobin oxygen
saturation (SpO2) and spirometry variables.
Spirometry was performed in patients older than seven
years of age with the CPFS/D spirometer (MedGraphics,
Saint Paul, MN, USA) and data were recorded using the
PF BREEZE software version 3.8B for Windows 95/98/NT
[33]. The following variables were included: forced vital
capacity [FVC(%)]; forced expiratory volume in the first
second [FEV1(%)], the ratio between FEV1 and FVC(%)
[FEV1/FVC(%)]; and forced expiratory flow between 25
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considering international curves values for spirometry
tests [34,35].
The comorbidities analyzed were nasal polyps, osteopor-
osis, meconium ileus, diabetes mellitus, and pancreatic in-
sufficiency. This study was approved by the Institutional
Ethics Committee from the Faculty of Medical Sciences,
University of Campinas (#528/2008), and all included
patients or their parents signed a consent form before
beginning the study.
CFTR mutation identification
CFTR mutation identification was performed by polymerase
chain reaction (PCR) for F508del and the fragment-length
polymorphism method for G542X, R1162X, R553X,
G551D, and N1303K mutations. Some CF mutations were
identified by sequencing or Multiplex Ligation-dependent
Probe Amplification (MLPA) analysis: S4X, 2183A > G,
1717-G > A, and I618T. A MegaBace1000® sequencer
(GE Healthcare Biosciences) was used for sequencing and
MLPA.
The CFTR genotype was used as a correction factor
for statistical analysis. All class I, II or III mutations, but
not class IV mutations (P205S and R334W), identified
were included in statistical analysis.
Identification of polymorphisms associated with GSH
metabolic pathway genes
Polymorphism identification was carried out using PCR
analysis. For GSTM1 and GSTT1 genes, a multiplex
PCR reaction was performed using the CYP1A1 gene
as an internal amplification control [36]. GCLC-129C >
T, -3506A > G [18,28] and GSTP1 + 313A > G [27] poly-
morphisms were identified by PCR followed by enzymatic
digestion.
Statistical analysis
Statistical analysis was performed using Statistical Package
for Social Sciences (SPSS) software version 21.0 (SPSS
Inc., Chicago, IL, USA), Epi Info version 6.0 [37] and R
version 2.12 (Comprehensive R Archive Network, 2011).
GPower 3.0.3.1 software [38] was used to calculate the
statistical power, which was required to be above 80% for
analysis.
Statistical tests included the analysis of variance
(ANOVA) and the chi-square (χ2) test (Odds Ratio -OR)
for GSTM1 and GSTT1, and the t-test and Fisher’s
exact test for GCLC-129C > T, GCLC-3506A > G and
GSTP1 + 313A > G polymorphisms. To avoid spurious
data caused by the performance of multiple tests [39], the
significance level (α) was adjusted by the Bonferroni cor-
rection (α corrected = 0.05/number of tests → 0.05/4 =
0.0125). The value of α was corrected considering clinicalmarker analysis of the same group of patients, taking into
account, the CFTR mutation genotype.
Data distribution showing a high standard deviation
was analyzed in groups distributed according to median
value. Variables that were adjusted by median to short
(more severe) and longtime were patient’s age, time to
diagnosis, onset of pulmonary and digestive symptoms,
and time to the first isolation of P. aeruginosa.
Analyses were performed of four cohorts: (i) all patients
with CF (n = 180); (ii) patients with no identified CFTR
mutation (n = 44); (iii) patients with an identified mutant
CFTR allele (Class I, II and/or III) (n = 51); and (iv) patients
with two identified CFTR mutations (Class I, II and/or III)
(n = 85). For (ii) and (iii) groups, a second analysis was per-
formed. In this case, CF patients with pancreatic sufficiency
(PS) were excluded. Patients with mutations Class I, II and
III for CFTR gene have severe disease, strongly associated
with pancreatic insufficiency (PI). Excluding PI patients was
a method to associated different CFTR mutation groups
with no atypical CF – associated less severe mutation
(Class IV, V and VI). After exclusion, we have in (ii) and
(iii) groups, respectively, 35 and 43 CF patients.
Results and discussion
One of the most intriguing aspects of CF is that patients
with the same CFTR genotype can present with pheno-
typic differences [40]. At our CF center, all patients receive
free medication provided by the state, have a similar socio-
economic status, share similar Class I, II and/or III muta-
tions, receive support from the Cystic Fibrosis Association
(http://www.fibrocis.org.br/), and there are no severe cases
of malnutrition. This therefore makes our sample more
phenotypically homogeneous for studies involving gene
modulation characteristics.
Variations in CF severity can be associated with a modi-
fier gene, such as those associated with oxidative stress
[19-21,26,30] that are related to chronic obstructive pul-
monary disease (COPD) [18]. The COPD pathophysiology
is similar, in some aspects, to CF in that it involves cellular
responses, inflammatory mediators, and oxidative stress
[41]. However, there is no mention in the scientific litera-
ture of GCLC polymorphisms as clinical modulators of CF
severity, and is necessary new studies to illuminate about
GST genes and CF severity.
One of the main functions of GSH is to detoxify xe-
nobiotics and their metabolites, and this function is
dependent on GST proteins. The GST gene family has
been linked with several diseases [22], as GSTM1,
GSTT1 and GSTP1 polymorphisms were found to be
associated with cancer, drugs, chemotherapy resistance
[42], and respiratory diseases such as asthma [30]. For
example, expression of the variant form of GSTP1
(where isoleucine is substituted for valine at codon
105) results in lower enzymatic activity, which is a risk
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diseases such as CF [43].
The effects of GSTM1, GSTT1 and GSTP1 polymor-
phisms on spirometry were previously investigated in
1,940 children (aged 8–11 years) [44]. The null GSTM1
genotype was associated with a decrease in annual FVC(%)
and FEV1(%) gain; likewise, homozygosity for the GSTP1
allele was linked with slower spirometric gain for the
same markers. The GSTM1 and GSTP1 genotypes there-
fore appear to be associated with spirometric evolution,
and could increase the severity of diseases of pulmo-
nary obstruction, depending on the genotype and gene
combination.
Table 1 shows the GCLC, GSTM1, GSTT1 and GSTP1
polymorphism distribution according to genotype in the
present study. The -129C > T polymorphism in the pro-
moter region of GCLC stimulates different responses to
oxidative stress by decreasing GSH production and re-
ducing cellular antioxidant capacity [45]. In the present
study, it was associated with a higher frequency of the
mucoid P. aeruginosa to CC genotype for GCLC-129C > T
polymorphism in patients with one CFTR mutation iden-
tified (Table 2; p = 0.044). This association may be related
to the lower GCLC protein expression in CC genotypes,
which reduces circulating GSH levels. The T allele is also
associated with increased GSH expression, as described in
protein expression studies on cardiovascular disease [45].
In the cited literature, we only found one study that
associated the GCLC polymorphism with CF severity.
In this previous study, the GAG micro-satellite GCLC
polymorphism was analyzed in 440 CF patients, and CFTR
mutations of lower gravity and highest number of GAG
repeats in the GCLC gene were associated with higher
values of FEV1(%) [20].Table 1 Distribution of GCLC, GSTM1, GSTT1 and GSTP1 polym
Gene Polymorphism Genotypes (N analyze
GCLC −129C > Ta CC CT
145 (80.11%) 29 (16.02%)
−3506A > Gb AA AG
119 (65.75%) 56 (30.94%)
M1 Deletionc - +
73 (40.33%) 108 (59.67%)
T1 Deletiond - +
63 (34.81%) 118 (65.19%)
M1/T1 Deletion −/− +/− and −/+
19 (10.50%) 99 (54.70%) 6
GSTP1 +313A > Gf AA AG
98 (54.14%) 74 (40.88%)
GSTM1, Glutathione S-transferase Mu; GSTT1, Glutathione S-transferase Theta 1; GST
subunit; N, Sample size; −, Null allele; +, Expressed allele.
The statistical association, taking into account the CFTRmutation groups, with the poly
b0.075 GCLC-3506A > G); c0.969 (M1); d0.088 (T1); e0,329 (GSTP1 + 313A > G)f.The GCLC-3506A > G polymorphism is not in Hardy-
Weinberg equilibrium as shown in Table 3, which also
shows the complete genotypic characteristics of GCLC,
GSTM1, GSTT1, and GSTP1 polymorphisms and CFTR
mutations in CF patients with regard to chromosomal pos-
ition, polymorphism location within the gene, and minor
allele frequency. GCLC-3506A > G was associated with a
higher frequency of the no mucoid P. aeruginosa to AA
genotype, and with a lower frequency of the no mucoid P.
aeruginosa to AG + GG genotype group in patients with
one CFTR mutation identified (Table 2; p = 0.012) and
higher Bhalla score values (without taking CFTR mutation
into account; p = 0.044).
The Bhalla score is associated with an impairment of
the pulmonary parenchyma structure and higher values
characterize major changes in thoracic tomography. Un-
expectedly, we also found that the greatest expression of
the A allele in the GCLC-3506A > G polymorphism did
not protect against no mucoid P. aeruginosa colonization.
However, protection against lung deterioration was evi-
dent when we considered the Bhalla score. This score was
also associated with GSTM1/GSTT1 deletions (p = 0.02),
with a lower frequency of heterozygous compared with
homozygous deletions. Moreover, the GSTT1 deletion
was found to be associated with SpO2 values (p = 0.048;
Table 4).
GCLC haplotype analysis for GCLC-129C > T and
GCLC-3506A > G showed association for A. xylosoxidans
and CC + AA genotypes (OR = 17.9; CI95% = 2.781-411.6;
Table 5).
The present study found that the AA genotype of the
GSTP1 + 313A > G polymorphism was associated with
a low risk of osteoporosis (p = 0.036; with two CFTR
mutations identified) as a protective factor and with youngorphisms
d and %) Grouping (N analyzed and %) Total
TT CC CT + TT 181 (100%)
7 (3.87%) 145 (80.11%) 36 (19.89%)
GG AA AG + GG 181 (100%)





GG AA AG + GG 181 (100%)
9 (4.98%) 98 (54.14%) 83 (45.86%)
P1, Glutathione S-transferase Pi 1; GCLC, Glutamate-cysteine ligase, catalytic
morphisms distribution was by p-values in the table: a0.880 (GCLC-129C > T);
Table 2 Polymorphisms in modifier genes associated with categorical variables of cystic fibrosis severity
CFTR group Polymorphism Genotype Variable pc OR CI (5–95%)
One CFTR mutation identified GCLC-129C > T PAM
Presence Absence Total
CC 25 17 42 0.044 11.27 1.6–272.6
CT + TT 1 8 9 - -
GCLC-3506A > G PANM
Presence Absence Total
AA 28 9 37 0.012 7.408 1.905–33.43
AG + GG 4 10 14 - -
No mutation identified GSTT1 gene deletion PANM
Presence Absence Total
Not expressed 13 9 21 0.008 7.895 2.095–34.96
Expressed 4 23 27 - -
One CFTR mutation identified + IP GSTM1 gene deletion Digestive symptoms
< 6 months ≥ 6 months
Not expressed 3 12 15 0.032 0.134 0.023-0.606
Expressed 14 7 21 - -
Two mutations identified GSTP1 + 313A > G Osteoporosis
Presence Absence Total
AA 2 42 44 0.036 0.141 0.028–0.687
AG + GG 9 26 35 - -
Without taking CFTR mutation into account Age (months)
≤ 154 > 154 Total
AA 58 39 97 0.044 2.198 1.208–4.037
AG + GG 33 49 82 - -
Statistical analysis was performed by Fisher’s exact test. CFTR, Cystic fibrosis transmembrane regulator; GCLC, Glutamate-cysteine ligase catalytic subunit; GSTM1,
Glutathione S-transferase mu 1; GSTT1, Glutathione S-transferase theta 1; GSTP1, Glutathione S-transferase Pi 1; PI, Pancreatic insufficiency; PAM, Pseudomonas
aeruginosa mucoid; PANM, Pseudomonas aeruginosa no mucoid; pc, P-value corrected by Bonferroni test; OR, Odds ratio; CI, Confidence interval.
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gene into account) as a risk factor. The G allele, however, is
responsible for increased GSTP1 expression. The presence
of osteoporosis is influenced by several different factors,
including mutations in the CFTR gene, the environment,
modifier genes, and increased life expectancy [46]. In this
context, in our data, the A allele is protective against
osteoporosis, and is increased among young patients with
unresolved CFTR mutation genotype. The osteoporosis
frequency is shown in Table 6.
The role of the GSTP1 polymorphism in CF hepatic
disease has previously been analyzed [19]. The authors
noted that CFTR protein expression was limited in liver
epithelium; however, recent discoveries indicate that CFTR
modulates the transport of GSH, creating a dysfunction
in the antioxidant defense [47]. Of the liver detoxifying
enzymes, GST plays a major role in protection against
oxidative stress. The impact of GSTM1 and GSTP1 was
also previously assessed in 106 CF patients where it was
verified that the frequency of the GG genotype for the
GSTP1 + 313A > G polymorphism was significantly higher
in CF patients with hepatic disease. This genotype wasassociated with an eight-fold increase in hepatic disease
risk in patients younger than six years of age. These find-
ings suggest that the identification of this polymorphism
may have prognostic and awareness values for the treat-
ment of CF patients with hepatic disease.
Considering the importance of the glutathione transport
versus CFTR protein-mediated, patients with residual
CFTR protein expression would have better performance
in the extracellular oxidative stress response being favor-
able for the passage of GSH to the outside by residual
CFTR activity. However, CF patients with two mutations
screened in CFTR gene have principally alternate routes
for the passing of GSH. Even taking into account that the
most of GSH is transferred to the external environment
via CFTR, in cases of residual CFTR (mutations Class IV,
V and VI) would be modified slightly in relation to the
GSH activity, since it is known that under 5% of CFTR ex-
pression occurs for minor severe CFTR mutations Classes,
and approximately 65% of GSH passage occurs via CFTR,
we had a percentage response to the GSH presence in ex-
ternal environment of at most 3.25% in cases of residual
CFTR. Considering this factor, the analysis excluding the
Table 3 Genotyping of GCLC, GSTM1, GSTT1, and GSTP1 polymorphisms and CFTR mutations
Gene Chromosomal position Location Polymorphism MAF HWE p-valuea
GCLC, rs17883901 6p12 Promoter region C > T 0.12 9.97 <0.005
GCLC, rs137852340 6p12 Promoter region A > G 0.19 0.04 >0.05
GSTP1, rs1695 11q13 Exon A > G 0.25 1.11 >0.05
GSTM1 1p13.3 Deletion
GSTT1 22q11.23 Deletion







F508del/1717-1G > A 1 0.56%
G542X/R1162X 1 0.56%
G542X/I618T 1 0.56%






MAF, Minor allele frequency; HWE, Hardy Weinberg Equilibrium; aP-value for Hardy-Weinberg Equilibrium; N, Number of patients; −, No identified CFTR mutation.
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and optimizes the response of the associations found in
our study.
Most studies analyzing the GSTP1 gene related it to
cancer and other diseases [22,30,44,48]. For example, the
AA genotype of the GSTP1 + 313A > G polymorphism was
shown to offer protection against asthmatic symptoms [22].
Indeed, the GSTP1 polymorphism was not previously found
to affect pulmonary function in CF patients [30]. In an
analysis of different genes involved in GST, there were no
differences in GST activity and antioxidant levels observed
between CF patients and controls. However, GST activity
was lower in P. aeruginosa-infected CF children with severeTable 4 Polymorphisms in modifier genes associated with nu
CFTR group Variable Polymorphism
Without taking CFTR mutation
into account
Bhalla scorea GCLC-3506A > G
No mutation identified SpO2a GSTT1 deletion
Bhalla scoreb GSTM1/GSTT1 deletions
aUsing Student’s t-test; bUsing analysis of variance.
CFTR, Cystic fibrosis transmembrane regulator; SpO2, Hemoglobin oxygen saturatioclinical symptoms, as was the frequency of the GSTP1 +
313A > G polymorphism AA genotype in uninfected (75%)
compared with infected (33%) children [21]. It is possible
that GST activity and GSTP1 genotype play an important
role in P. aeruginosa infection in CF patients. In support
of this, the G allele of the GSTP1 gene appears to be asso-
ciated with an increased risk of severe pulmonary disease
[21]. However, in a previous investigation into GSTM1
and GSTP1 polymorphisms in patients with CF and
COPD, no significant associations were found between
GSTM1 activity and pulmonary disease severity. An
analysis of genotypic combinations for GSTM1 and GSTP1
polymorphic loci showed that changes in GSTP1 activitiesmerical variables of cystic fibrosis severity
Genotype N Mean SD SEM p- value corrected
AA 94 19.70 6.007 0.620 0.044
AG + GG 43 17.00 5.033 0.768
Not expressed 15 96.13 2.232 0.576 0.048
Expressed 29 93.17 5.245 0.974
−/− 4 14.75 1.258 0.629 0.02
+/− and −/+ 21 6.900 6.610 1.442
+/+ 9 15.33 7.533 2.511
n in the blood; −, Null allele; +, Expressed allele; N, Number of patients.
Table 5 GCLC-129C > T and GCLC-3506A > G haplotype polymorphisms in modifier genes associated with categorical
variables of cystic fibrosis severity
CFTR group PI taking
into account





No GCLC-129C > T + GCLC-3506A > G CC + AA 10 26 36 17.9 2.781-411.6
CC + (AG or GG) 1 30 31 0.024 0.149 0.007-0.959
(CT or TT) + GG 0 13 13 - -
TT + GG 0 5 5 - -
Statistical analysis was performed by χ2 test. CFTR, Cystic fibrosis transmembrane regulator; GCLC, Glutamate-cysteine ligase catalytic subunit; PI, Pancreatic
insufficiency; AX, Achromobacter xylosoxidans; pc, P-value corrected by Bonferroni test; OR, Odds ratio; CI, Confidence interval.
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GSTM1 gene deletions may not themselves be implicated
in pathogenesis, they may aggravate the disease in combin-
ation with GSTP1 polymorphisms. Perhaps the strongest
performance for the GSTP1 gene in CF may result from
the primary expression of this GST in the airways [48].
The present study showed that the homozygous deletion
in GSTT1 was a no mucoid P. aeruginosa risk factor in
the no CFTR mutation group (p = 0.008; Table 2) and a
protective factor for low values of SpO2. GSTT1 expres-
sion is likely to act in the inflammatory response of the
pulmonary parenchyma. As chronic airway infection by
no mucoid P. aeruginosa is associated with greater clinical
severity [49], the GSTT1 polymorphism may be associated
with the presence of P. aeruginosa through different
mechanisms, including a low antioxidant response leading
to further pulmonary degradation and the formation of
a favorable environment for no mucoid P. aeruginosa
colonization or infection.
The mechanism of gene action that determines which
bacteria can colonize the lungs of CF patients is not fully
understood. Similarly, it is also unclear which microor-
ganisms are risk factors for the disease. Therefore, con-
firmation of a gene acting as modulator of an important
metabolic pathway, such as GSH, may open up novel ways
to identify the genetic factors that determine the severity
of pulmonary disease. Future pharmacogenetic studiesTable 6 Age’s distribution and osteoporosis among CFTR mut













51 201.18 165.050 15
Two mutation
identified
84 220.06 188.643 17
Pancreatic insufficiency One CFTR
mutation identified
35 221.57 216.17 14
Two mutation
identified
43 198.81 171.31 14
CFTR, Cystic fibrosis transmembrane regulator; N, number of patients.could then use this knowledge to provide new CF
therapies.
Many previous studies have revealed that polymor-
phisms of GSTM1 and GSTT1 are associated with cancer
[22,24,50,51], but few have been conducted in CF. Fifty-
three children with CF were studied by Hull and Thomson
[26], of which 26 with the GSTM1 null allele had a signifi-
cantly lower Shwachman-Kulczycki score. This supports
the hypothesis that inflammation in CF contributes to tis-
sue injury. Indeed, GSTM1 null alleles can be a risk factor
for pulmonary diseases in individuals with a reduced ability
to deal with oxidants. There is also evidence that a high
level of oxidative stress in the lungs of CF patients is caused
by the release of reactive oxygen species by neutrophils
[26]. In the present study, we found that expression of
only one allele of GSTM1 and GSTT1 polymorphisms was
associated with a low Bhalla score in patients with no
CFTR mutation identified.
An interesting aspect was the high frequency of PS
patients. The presence of PS occurred at exactly 20% of
the sample. However, there was no difference distribu-
tion between the groups of patients with CF taking into
account CFTR mutations groups (p = 0.621). Patients
with two mutations identified in CFTR gene had 22.36%
(19/85) of PS, values close to the other groups of patients
[one identified mutation and no mutation identified with,











5.62 277.88 25 932 8 (19%)
4.76 247.60 11 782 0.854 9 (17.6%)
9.12 261.00 7 1274 12 (14.3%)
0.761
7.31 295.83 25 932
7 (21.2%)
6.09 251.54 11 782 0.940
5 (11.6%)
0.345
Table 7 Patient characteristics (n = 180)
Characteristic
Male gender 50% (90)
Age (months) 212 ± 15.75 (7–288)
Caucasoid 91.75%
BMI - thinness and accentuated thinness 22.22% (40)
One class I, II or III identified mutation 28.33% (51)
Two class I, II or III identified mutations 47.22% (85)
Age at first clinical manifestation (months) 35 ± 8.88 (0–156)
Age at diagnosis (months) 87 ± 13.63 (0–170.76)
Age at start of digestive symptoms (months) 40.6 ± 9.11 (0–149.4)
Age at start of pulmonary symptoms (months) 34.8 ± 9.88 (0–1156)
SpO2(%) 94.92 ± 4.26 (66–99)
Bhalla 8.74 ± 5.72 (0–25)
Kanga 18.85 ± 5.84 (10–40)
Shwachman-Kulczycki 65.85 ± 16.77 (20–95)
FVC(%) 79.29 ± 23.55 (19–135)
FEV1(%) 71.29 ± 27.467 (17–132)
FEV1/FVC(%) 83.46 ± 15.95 (37–137)
FEF25–75% 59.05 ± 35.55 (7–150)
Nasal polyps 18.33% (33)
Diabetes mellitus 18.33% (33)
Osteoporosis 16.11% (29)
Pancreatic insufficiency 80.0% (144)
Meconium ileus 15.00% (27)
Age at first isolated P. aeruginosa (months) 102.6 ± 14.45 (24–180)
P. aeruginosa statusa 56.67% (102)
P. aeruginosa mucoid statusa 42.22% (76)
B. cepacia statusa 13.88% (25)
A. xylosoxidans statusa 10.00% (18)
S. aureus statusa 78.88% (142)
Continuous variables expressed as mean ± SD (range). Other data shown as
percentage (number of patients). aBased on three consecutive positive
respiratory cultures.
N, Sample size; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in
the blood; FVC, Forced vital capacity; FEV1, Forced expiratory volume in the
first second; FEF25–75, Forced expiratory flow between 25 and 75% of FVC.
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http://www.biomedcentral.com/1471-2350/15/27The PI is an important clinical marker of CF and is
considered associated with the severity of disease and
severe CFTR mutations (Class I, II and/or III). Studies
considering populations of patients with CF, as performed
by the Cystic Fibrosis Foundation give the prevalence of
PI ranging from 5-10%. In our study, the high prevalence
of PI may be associated with: (i) presence of higher fre-
quency of mutations Class IV, V and/or VI, (ii) presence of
modifier genes acting on the symptom of the disease, (iii)
high miscegenation could be a protective factor for PI, (iv)
environmental factor as an unknown protector.
The PI was used in statistical analysis as factor correction
for no determination of CFTR mutation in CF groups
with no or one CFTR mutation screened. After the patient
exclusion to statistical analysis, all the previous positive
associations were negative, except for GSTM1 null allele.
The null allele was associated as protector factor for
onset of digestive symptoms (OR= 0.134; CI = 0.023-0.606;
Table 2).
One important aspect considered was the age. Before
the statistical analysis, the age was considered between
the CFTR mutations groups (p = 0.854). The same occurred
for CFTR mutations groups + insufficiency pancreatic
(p = 0.940) (Table 6). No positive association was find
considering age.
The divergent immune response is associated with
multiple factors that denote the CF complexity such as
the multigenic response, environmental influences, and
interaction between airway microorganisms [49,52]. Clin-
ically severe patients may have high initial inflammatory
response, characterizing CF as a disease where inflamma-
tion occurs prior to infection [53]. Polymorphisms in genes
that are involved in inflammation may be a risk factor for
early severity of the disease [1], and patients with airways
colonized by bacteria suffer early clinical deterioration and
high levels of airway inflammation [54].
For the same population, a first study taking into account
the same polymorphisms and clinical variables was per-
formed. The previous data analyzed the genetic interaction
among GST and GCLC polymorphisms, CFTR mutations
and clinical markers. The data showed an interaction of
GSTM1 and GSTT1 genes deletion, GSTP1* + 313A > G,
and CFTR mutations (p = 0.008) and Bhalla clinical score
by multifactor dimensionality reduction test. The Bhalla
score is a computed tomography, which measures pul-
monary involvement, therapeutic effects and selection
of patients for transplantation, which detects anatomical
changes of the lung parenchyma. The data published
showed a first step to understand the complex mech-
anisms associated with the CF severity and modifier
genes [55].
In the present study, we studied a CF population with
complex clinical characteristics. By considering the dif-
ferent possible groupings of polymorphisms and clinicalvariables (Table 7) in relation to the CFTR gene, we
performed various association studies. Supplementary
data for GCLC-129C > T, GCLC-3506A > G, GSTM1 gene
deletion, GSTT1 gene deletion, GSTM1/GSTT1 gene dele-
tions and GSTP1* + 313A > G are shown in Tables 8, 9,
10, 11, 12, 13 and 14. Further multicenter studies should
be conducted to verify the influence of modifier genes in
different CFTR genotypes.
Study limitations: (i) CFTR mutation with no complete
screening; (ii) short population of CF patients; (iii) spir-
ometry test performed by transversal method and did no
performed longitudinally; (iv) no measure of GSH activity
or GST and GCLC proteins, taking into account the sam-
ple collection limitation in our center and time to process
Table 8 GCLC-129C > T polymorphism associated with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.577 1 1 1 1 1 0.024 0.096 0.698 1 0.418 1
Agea 0.348 1 1 1 0.667 1 1 1 1 1 0.249 0.996
Onset of symptomsa 1 1 0.165 0.660 0.401 1 1 1 1 1 0.392 1
Onset of pulmonary diseasea 0.162 0.648 1 1 1 1 0.409 1 0.685 1 0.168 0.672
Onset of digestive diseasea 1 1 0.142 0.568 0.354 1 0.710 1 0.650 1 0.583 1
Diagnosisa 1 1 1 1 0.405 1 0.715 1 0.412 1 0.764 1
BMIa 1 1 0.414 1 0.559 1 0.331 1 1 1 1 1
Bhalla scoreb 0.626 1 0.47 1 0.023 0.092 0.851 1 0.090 0.360 0.834 1
Kanga scoreb 0.277 1 0.45 1 0.632 1 0.687 1 0.625 1 0.192 0.768
Shwachman-Kulczycki scoreb 0.917 1 0.532 1 0.041 0.164 0.405 1 0.435 1 0.767 1
Nasal polyposisa 0.811 1 0.66 1 0.555 1 0.332 1 0.577 1 0.066 0.264
Diabetes mellitusa 0.811 1 1 1 1 1 1 1 0.315 1 0.505 1
Osteoporosisa 0.306 1 1 1 0.299 1 0.353 1 1 1 0.238 0.952
Meconium ileus 0.792 1 1 1 0.576 1 0.651 1 0.147 0.588 0.727 1
Pancreatic insufficiencya 0.063 0.252 0.267 1 - - 0.328 1 1 1
SpO2b 0.384 1 0.296 1 0.078 0.312 0.124 0.496 0.864 1 0.597 1
FVC(%)b 0.822 1 0.828 1 0.127 0.508 0.922 1 0.506 1 0.597 1
FEV1(%)
b 0.598 1 0.310 1 0.160 0.640 0.983 1 0.510 1 0.820 1
FEV1/FVC
b 1 1 0.109 0.436 0.386 1 0.873 1 0.820 1 0.170 0.680
FEF25–75%
b 0.448 1 0.044 0.176 1 1 0.982 1 0.767 1 0.537 1
First P. aeruginosaa 1 1 1 1 0.691 1 0.695 1 0.361 1 1 1
P. aeruginosa mucoida 0.133 0.532 1 1 0.689 1 0.011 0.044 0.427 1 1 1
P. aeruginosa no mucoida 1 1 1 1 1 1 0.266 1 0.680 1 0.391 1
A. xylosoxidansa 0.534 1 1 1 1 1 1 1 1 1 1 1
S. aureusa 0.261 1 0.093 0.372 1 1 1 1 1 1 1 1
B. cepaciaa 1 1 1 1 1 1 1 1 0.318 1 1 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; PI, Pancreatic insufficiency; GCLC, Glutamate cysteine ligase catalytic subunit; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital




















Table 9 GCLC-3506A > G polymorphism in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.753 1 0.532 1 1 1 0.149 0.596 0.510 1 0.824 1
Agea 0.057 0.228 0.710 1 0.245 0.980 0.541 1 1 1 0.339 1
Onset of symptomsa 1 1 1 1 0.420 1 0.731 1 0.078 0.312 0.812 1
Onset of pulmonary diseasea 0.507 1 1 1 0.152 0.608 0.727 1 0.302 1 0.816 1
Onset of digestive diseasea 0.865 1 0.646 1 0.408 1 1 1 0.158 0.632 1 1
Diagnosisa 0.335 1 0.419 1 1 1 0.330 1 1 1 1 1
BMIa 1 1 1 1 0.281 1 0.704 1 0.709 1 0.785 1
Bhalla scoreb 0.35 1 0.830 1 0.468 1 0.169 0.676 0.833 1 0.495 1
Kanga scoreb 0.011 0.044 0.734 1 0.788 0.067 0.268 0.588 1 0.027 0.108
Shwachman-Kulczycki scoreb 0.091 0.364 0.725 1 0.223 0.892 0.034 0.136 0.545 1 0.159 0.636
Nasal polyposisa 0.688 1 0.251 1 0.555 1 0.692 1 1 1 0.083 0.332
Diabetes mellitusa 0.688 1 1 1 1 1 0.419 1 0.217 0.868 1 1
Osteoporosisa 0.133 0.532 1 1 0.068 0.272 0.25 1 0.630 1 0.335
Meconium ileus 1 1 1 1 0.304 1 1 1 0.417 1 1 1
Pancreatic insufficiencya 0.698 1 0.180 0.720 - - 0.376 1 - - 1 1
SpO2b 0.033 0.132 0.234 0.936 0.142 0.568 0.548 1 0.134 0.536 0.149 0.596
FVC(%)b 0.412 1 0.944 1 0.061 0.244 0.036 0.144 0.755 1 0.955 1
FEV1(%)
b 0.166 0.664 0.877 1 0.094 0.376 0.030 0.120 0.381 1 0.577 1
FEV1/FVC
b 0.054 0.216 0.912 1 0.403 1 0.050 0.200 0.247 0.988 0.111
FEF25–75%
b 0.061 0.244 0.934 1 0.177 0.708 0.029 0.116 0.577 1 0.272 1
First P. aeruginosaa 0.350 1 0.453 1 0.433 1 0.716 1 0.015 0.060 0.799 1
P. aeruginosa mucoida 0.152 0.608 1 1 0.443 1 0.064 0.256 0.178 0.712 0.371 1
P. aeruginosa no mucoida 0.057 0.228 1 1 0.243 0.972 0.003 0.012 0.023 0.092 0.351 1
A. xylosoxidansa 0.187 0.748 0.066 0.044 0.176 0.565 1 1 1 0.343 1
S. aureusa 0.849 1 0.708 1 1 1 0.376 1 0.024 0.096 0.394 1
B. cepaciaa 0.246 0.984 1 1 1 1 0.471 1 0.082 0.328 0.394 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GCLC, Glutamate cysteine ligase catalytic subunit; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital




















Table 10 GCLC-129C > T and GCLC-3506A > G polymorphisms by haplotype in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.285 1 0.302 1 0.505 1 0.424 1 0.479 1 0.223 0.892
Agea 0.437 1 0.639 1 0.382 1 0.601 1 0.777 1 0.625 1
Onset of symptomsa 0.098 0.392 0.407 1 0.421 1 0.143 0.572 0.180 0.720 0.036 0.144
Onset of pulmonary diseasea 0.802 1 0.091 0.364 0.163 0.652 0.424 1 0.321 1 0.980 1
Onset of digestive diseasea 0.640 1 0.237 0.948 0.311 1 0.692 1 0.318 1 0.452 1
Diagnosisa 0.334 1 0.620 1 0.637 1 0.715 1 0.613 1 0.218 0.872
BMIa 0.620 1 0.376 1 0.510 1 0.848 1 0.754 1 0.665 1
Bhalla scoreb 0.942 1 0.808 1 0.158 0.632 0.830 1 0.324 1 0.311 1
Kanga scoreb 0.879 1 0.884 1 0.805 1 0.753 1 0.745 1 0.822 1
Shwachman-Kulczycki scoreb 0.985 1 0.416 1 0.151 0.604 0.538 1 0.837 1 0.981 1
Nasal polyposisa 0.582 1 0.347 1 0.285 1 0.457 1 0.631 1 0.986 1
Diabetes mellitusa 0.255 1 0.858 1 0.917 1 0.201 0.804 0.337 1 0.383 1
Osteoporosisa 0.562 1 0.829 1 0.108 0.432 0.339 1 0.036 0.144 0.713 1
Meconium ileus 0.420 1 0.389 1 0.379 1 0.130 0.520 0.080 0.320 0.619 1
Pancreatic insufficiencya 0.159 0.636 0.398 1 - - 0.167 0.668 - - 0.601 1
SpO2b 0.506 1 0.201 0.804 0.128 0.512 0.422 1 0.525 1 0.278 1
FVC(%)b 0.498 1 0.216 0.864 0.121 0.484 0.738 1 0.901 1 0.499 1
FEV1(%)
b 0.668 1 0.214 0.856 0.201 0.804 0.479 1 0.731 1 0.769 1
FEV1/FVC
b 0.615 1 0.592 1 0.671 1 0.407 1 0.686 1 0.373 1
FEF25–75%
b 0.643 1 0.326 1 0.531 1 0.548 1 0.942 1 0.851 1
First P. aeruginosaa 0.147 0.588 0.125 0.500 0.341 1 0.146 0.584 0.027 0.108 0.264 1
P. aeruginosa mucoida 0.559 1 0.316 1 0.366 1 0.569 1 0.285 1 0.160 0.640
P. aeruginosa no mucoida 0.319 1 0.263 1 0.352 1 0.276 1 0.082 0.328 0.347 1
A. xylosoxidansa 0.327 1 0.018 0.072 0.013 0.052 0.687 1 0.646 1 0.006 0.024
S. aureusa 0.843 1 0.677 1 0.931 1 0.049 0.196 0.032 0.128 0.466 1
B. cepaciaa 0.461 1 0.734 1 0.974 1 0.150 0.600 0.243 0.972 0.671 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GCLC, Glutamate cysteine ligase catalytic subunit; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital




















Table 11 GSTM1 deletion polymorphism in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.171 0.684 0.764 1 0.075 0.300 0.267 1 0.537 1 0.110 0.440
Agea 1 1 0.498 1 0.736 1 0.579 1 1 1 1 1
Onset of symptomsa 0.268 1 0.459 1 0.721 1 1 1 1 1 0.629 1
Onset of pulmonary diseasea 0.424 1 0.068 0.272 1 1 1 1 0.742 1 0.639 1
Onset of digestive diseasea 0.409 1 0.665 1 1 1 1 1 0.008 0.032 0.635 1
Diagnosisa 1 1 0.059 0.236 0.729 1 0.149 0.596 1 1 1
BMIa 0.462 1 0.503 1 0.115 0.460 0.725 1 1 1 0.169 0.676
Bhalla scoreb 0.86 1 0.11 0.44 0.059 0.236 0.050 0.200 0.692 1 0.879 1
Kanga scoreb 0.982 1 0.693 1 0.367 1 0.822 1 0.480 1 0.784 1
Shwachman-Kulczycki scoreb 0.501 1 0.449 1 0.884 1 0.123 0.492 0.777 1 0.568 1
Nasal polyposisa 0.331 1 0.136 0.544 0.610 1 1 1 0.407 1 0.765 1
Diabetes mellitusa 0.560 1 1 1 1 1 0.703 1 1 1 0.169 0.676
Osteoporosisa 0.217 0.868 0.435 1 0.377 1 0.173 0.633 1 1 1
Meconium ileus 1 1 1 1 0.640 1 0.726 1 1 1 0.776 1
Pancreatic insufficiencya 1 1 0.765 1 - - 1 1 - - 1 1
SpO2b 0.187 0.748 0.012 0.048 0.500 1 0.780 1 0.652 1 0.645 1
FVC(%)b 0.990 1 0.741 1 0.020 0.08 0.538 1 0.307 1 0.967 1
FEV1(%)
b 0.827 1 0.623 1 0.030 0.012 0.786 1 0.972 1 0.943 1
FEV1/FVC
b 0.915 1 0.749 1 0.532 1 0.918 1 0.244 0.976 0.597 1
FEF25–75%
b 0.853 1 0.718 1 0.197 0.788 0.819 1 0.255 1 0.847 1
First P. aeruginosaa 0.724 1 1 1 0.473 1 0.056 0.224 1 1 0.312 1
P. aeruginosa mucoida 0.092 0.368 0.729 1 0.289 1 1 1 0.541 1 0.107 0.428
P. aeruginosa no mucoida 0.879 1 0.754 1 0292 1 0.776 1 1 1 0.629 1
A. xylosoxidansa 0.619 1 0.537 1 1 1 0.35 1 0.511 1 0.52 1
S. aureusa 0.362 1 0.175 0.700 0.391 1 1 1 1 1 0.776 1
B. cepaciaa 0.371 1 0.116 0.464 0.313 1 0.703 1 1 1 1 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GSTM1, Glutathione S-transferase mu 1; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital capacity;




















Table 12 GSTT1 deletion polymorphism in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.211 0.844 0.778 1 0.378 1 1 1 0.215 0.860 0.081 0.324
Agea 0.043 0.166 0.750 1 0.505 1 0.083 0.332 0.531 1 0.795 0.795
Onset of symptomsa 1 1 0.305 1 1 1 0.202 0.808 0.746 1 0.600 1
Onset of pulmonary diseasea 0.620 1 0.721 1 0.229 0.916 0.521 1 0.746 1 0.796 1
Onset of digestive diseasea 0.863 1 0.390 1 1 1 0.344 1 0.179 0.716 1 1
Diagnosisa 0.745 1 1 1 0.303 1 0.068 0.272 0.537 1 0.779 1
BMIa 0.447 1 0.747 1 0.103 0.412 0.295 1 0.728 1 0.537 1
Bhalla scoreb 0.485 1 0.824 1 0.134 0.536 0.322 1 0.634 1 0.185 0.740
Kanga scoreb 0.737 1 0.743 1 0.421 1 0.953 1 0.321 1 0.767 1
Shwachman-Kulczycki scoreb 0.734 1 0.984 1 0.013 0.052 0.653 1 0.925 1 0.393 1
Nasal polyposisa 0.313 1 1 1 1 1 0.062 0.248 0.685 1 1 1
Diabetes mellitusa 0.158 0.632 0.115 0.460 0.398 1 0.450 1 0.071 0.284 0.764 1
Osteoporosisa 1 1 1 1 0.085 0.340 1 1 0.230 0.920 0.718 1
Meconium ileus 0.276 1 0.077 0.308 0.658 1 1 1 0.445 1 0.335 1
Pancreatic insufficiencya 0.847 1 0.561 1 - - 1 1 - - 0.557 1
SaO2b 0.988 1 0.740 1 0.170 0.680 0.595 1 0.333 1 0.703 1
FVC(%)b 0.268 1 0.086 0.344 0.154 0.616 0.464 1 0.412 1 0.623 1
FEV1(%)
b 0.310 1 0.167 0.668 0.029 0.116 0.564 1 0.597 1 0.636 1
FEV1/FVC
b 0.404 1 0.288 1 0.017 0.068 0.692 1 0.676 1 0.424 1
FEF25–75%
b 0.687 1 0.390 1 0.027 0.108 0.686 1 0.829 1 0.959 1
First P. aeruginosaa 0.472 1 1 1 0.724 1 0.320 1 0.713 1 0.085 0.340
P. aeruginosa mucoida 0.433 1 0.747 1 1 1 0.393 1 0.753 1 1 1
P. aeruginosa no mucoida 0.876 1 0.002 0.008 0.489 1 0.133 0.266 0.541 1 1 1
A. xylosoxidansa 0.437 1 1 1 0.338 1 0.623 1 0.151 0.604 0.295 1
S. aureusa 0.705 1 1 1 0.658 1 0.325 1 0.735 1 1 1
B. cepaciaa 1 1 1 1 0.177 0.708 0.699 1 0.407 1 0.215 0.860
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GSTT1, Glutathione S-transferase theta 1; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital capacity;




















Table 13 GSTM1/GSTT1 deletion polymorphism in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.036 0.144 0.943 1 0.601 1 0.369 1 0.114 0.456 0.014 0.056
Agea 0.331 1 0.647 1 0.496 1 0.054 0.216 0.149 0.596 0.908 1
Onset of symptomsa 0.300 1 0.996 1 0.835 1 0.579 1 0.854 1 0.049 0.196
Onset of pulmonary diseasea 0.588 1 0.359 1 0.431 1 0.776 1 0.267 1 0.559 1
Onset of digestive diseasea 0.626 1 0.480 1 0.581 1 0.433 1 0.458 1 0.051 0.204
Diagnosisa 0.520 1 0.207 0.828 0.490 1 0.710 1 0.510 1 0.992 1
BMIa 0.283 1 0.954 1 0.717 1 0.252 1 0.998 1 0.596 1
Bhalla scoreb 0.088 0.352 0.005 0.02 0.915 1 0.381 1 0.218 0.872 0.481 1
Kanga scoreb 0.885 1 0.443 1 0.216 0.864 0.912 1 0.261 1 0.455 1
Shwachman-Kulczycki scoreb 0.627 1 0.144 0.576 0.087 0.348 0.387 1 0.104 0.416 0.195 0.780
Nasal polyposisa 0.098 0.392 0.483 1 0.699 1 0.467 1 0.362 1 0.102 0.408
Diabetes mellitusa 0.259 1 0.240 0.96 0.790 1 0.992 1 0.555 1 0.334 1
Osteoporosisa 0.204 0.816 0.501 1 0.525 1 0.427 1 0.187 0.748 0.386 1
Meconium ileus 0.683 1 0.266 1 0.348 1 0.517 1 0.905 1 0.626 1
Pancreatic insufficiencya 0.965 1 0.791 1 - - 0.975 1 - - 0.653 1
SpO2b 0.449 1 0.021 0.084 0.557 1 0.616 1 0.774 1 0.786 1
FVC(%)b 0.576 1 0.518 1 0.859 1 0.928 1 0.475 1 0.758 1
FEV1(%)
b 0.778 1 0.182 0.728 0.977 1 0.799 1 0.827 1 0.657 1
FEV1/FVC
b 0.178 1 0.007 0.028 0.265 1 0.789 1 0.395 1 0.593 1
FEF25–75%
b 0.881 1 0.014 0.056 0.751 1 0.719 1 0.370 1 0.382 1
First P. aeruginosaa 0.545 1 0.686 1 0.295 1 0.019 0.076 0.299 1 0.123 0.492
P. aeruginosa mucoida 0.134 0.536 0.118 0.472 0.492 1 0.575 1 0.940 1 0.337 1
P. aeruginosa no mucoida 0.487 1 0.051 0.204 0.682 1 0.167 0.668 0.190 0.760 0.847 1
A. xylosoxidansa 0.541 1 0.779 1 0.663 1 0.079 1 0.537 1 0.995 1
S. aureusa 0.660 1 0.243 0.972 0.839 1 0.716 1 0.181 0.724 0.667 1
B. cepaciaa 0.861 1 0.142 0.568 0.054 1 0.759 1 0.145 0.580 0.640 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GSTM1, Glutathione S-transferase mu 1; GSTT1, Glutathione S-transferase theta 1; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation




















Table 14 GSTP1 + 313A > G polymorphism in association with CF clinical variables as distributed by CFTR mutation












p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected p-value p-corrected
Gendera 0.550 1 0.396 1 1 1 0.267 1 0.763 1 0.184 0.736
Agea 0.011 0.044 0.750 1 0.500 1 0.051 0.204 1 1 0.058 0.232
Onset of symptomsa 0.876 1 0.473 1 0.720 1 1 1 0.531 1 1 1
Onset of pulmonary diseasea 0.754 1 0.729 1 0.252 1 0.757 1 0.757 1 1 1
Onset of digestive diseasea 0.516 1 1 1 0.462 1 0.761 1 1 1 1 1
Diagnosisa 0.644 1 0.694 1 0.185 0.740 0.561 1 0.763 1 0.441 1
BMIa 0.856 1 0.331 1 1 1 1 1 0.488 1 1 1
Bhalla scoreb 0.098 0.392 0.187 1 0.671 1 0.491 1 0.098 0.392 0.392 1
Kanga scoreb 0.716 1 0.867 1 0.604 1 0.407 1 0.416 1 0.300 1
Shwachman-Kulczycki scoreb 0.554 1 0.984 1 0.121 0.484 0.73 1 0.198 0.792 0.170 0.680
Nasal polyposisa 0.848 1 0.306 1 0.601 1 1 1 0.412 1 0.562 1
Diabetes mellitusa 0.336 1 1 1 1 1 0.703 1 1 1 0.582 1
Osteoporosisa 0.159 0.318 0.715 0.953 1 1 0.345 1 0.009 0.036
Meconium ileus 0.403 1 1 1 0.398 1 1 1 0.457 1 0.161 0.644
Pancreatic insufficiencya 0.581 1 0.393 1 0.187 0.748 0.703 1 - - 0.578 1
SpO2b 0.967 1 0.839 1 0.230 0.920 0.156 0.624 0.157 0.628 0.346 1
FVC(%)b 0.441 1 0.407 1 0.279 1 0.849 1 0.315 1 0.626 1
FEV1(%)
b 0.338 1 0.467 1 0.923 1 0.907 1 0.221 0.884 0.451 1
FEV1/FVC
b 0.295 1 0.265 1 0.218 0.872 0.575 1 0.771 1 0.439 1
FEF25–75%
b 0.146 0.584 0.498 1 0.261 1 0.505 1 0.379 1 0.291 1
First P. aeruginosaa 0.035 0.140 1 1 0.473 1 0.056 0.224 1 1 0.203 0.812
P. aeruginosa mucoida 0.289 1 0.331 1 0.505 1 0.782 1 0.760 1 0.653 1
P. aeruginosa no mucoida 1 1 0.548 1 1 1 0.776 1 0.760 1 0.482 1
A. xylosoxidansa 0.806 1 0.196 0.784 1 1 0.350 1 0.488 1 0.755 1
S. aureusa 0.721 1 0.507 1 1 1 0.743 1 0.185 0.740 0.565 1
B. cepaciaa 0.667 1 0.196 0.784 1 1 0.703 1 0.698 1 0.404 1
aFisher’s exact test used for categorical variables; bStudent’s t-test used for numerical variables. P-values < 0.05 denote clinical association (bold).
CFTR, Cystic fibrosis transmembrane regulator; GSTP1, Glutathione S-transferase pi 1; PI, Pancreatic insufficiency; BMI, Body mass index; SpO2, Hemoglobin oxygen saturation in the blood; FVC, Forced vital capacity;
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collection – considering an admixed population, the
CF patients from one center minimizes miscegenation
factors. Another fact, is the similar environmental and
the same access to treatment; (ii) high number of clinical
markers evaluated provides better association and charac-
terization of modifier genes action; (iii) complete CF diag-
nosis performed by different methods.
Conclusions
Our results show that, although a monogenic disease, CF
is heavily influenced in its clinical characteristics, evolu-
tion and severity by polymorphisms in modifier genes.
Nevertheless, there is still a long way before the dynamics
of polymorphisms in genes active in the GSH metabolic
pathway and involved in detoxification in CF are fully
understood.
Another fact is the prevalence of PS and PI that should
be considered in all studies in the future, being associated
with different phenotype and genotype.
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